2024-10-09 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis

**1. Performance Comparison:**

Pfizer Inc. (PFE) is a pharmaceutical company that develops and manufactures drugs and vaccines.  Its stock has underperformed significantly compared to the S&P 500 (VOO) over the period considered. The cumulative return of PFE is -12.94%, while the VOO's return is 133.14%, resulting in a substantial divergence of -146.08. This places PFE at the 25th percentile of its historical relative performance compared to VOO.

**2. Recent Price Action:**

As of today, PFE's closing price is $28.58.  The stock is trading below its 5-day, 20-day, and 60-day moving averages, indicating a downward trend.

* 5-Day Moving Average: $28.63
* 20-Day Moving Average: $29.24
* 60-Day Moving Average: $29.28

**3. Technical Indicators:**

* **RSI (21.8):** The RSI is below 30, indicating that PFE is oversold. This suggests potential for a rebound in the short term.
* **PPO (-0.39):**  The PPO is negative, implying a bearish momentum in the price. This aligns with the recent price trend.
* **Delta_Previous_Relative_Divergence (-7.79):** This indicator suggests a recent downward trend in the stock's performance relative to its historical trend. 
* **Expected Return (0.0%):** This suggests that, based on historical data, there is no anticipated outperformance of PFE compared to VOO over the next 5 years.

**4. Recent Earnings and Outlook:**

Pfizer's most recent earnings were reported on July 30, 2024.  The company reported EPS of $0.60, which exceeded analysts' expectations of $0.458. This positive earnings surprise could potentially boost the stock price in the short term. 

| Date       | EPS    | Expected EPS |
|------------|--------|--------------|
| 2024-07-30 | 0.60   | 0.458        |
| 2024-05-01 | 0.82   | 0.516        |
| 2024-01-30 | 0.10   | -0.19        |
| 2023-10-31 | -0.17  | -0.32        |
| 2023-08-01 | 0.67   | 0.56         |

**5. News and Recent Events:**

* **Recent Market Outlook for PFE:** 
    * **Analyst Opinions:**  Analysts remain mixed on PFE's future prospects, with some expressing concern about the company's long-term growth potential, especially as its COVID-19 vaccine sales decline. 
    * **Performance Highlights:** Recent performance highlights include the success of its blockbuster drug, Paxlovid, in treating COVID-19 and the expansion of its portfolio through strategic partnerships and acquisitions.  However,  the company's reliance on a few key products, including the COVID-19 vaccine, presents a risk to its future earnings.
* **Recent News:** 
    * Pfizer recently announced a collaboration with Moderna to develop new mRNA vaccines.
    *  There are ongoing concerns about the emergence of new COVID-19 variants and their potential impact on the demand for Pfizer's vaccines.


**6. Overall Analysis:**

Pfizer's stock has significantly underperformed the S&P 500 in recent times, although it did show a positive earnings surprise in its latest report.  While the stock is currently oversold, technical indicators suggest bearish momentum, and analysts remain mixed on the company's future prospects.  Given the current market outlook and the company's reliance on a few key products, investors should proceed with caution.

**7. Report:**

This analysis provides a comprehensive overview of Pfizer Inc. (PFE) stock based on historical data, recent price action, technical indicators, earnings, and current market sentiment. 
While PFE is currently oversold and has experienced a recent earnings beat, a number of factors warrant caution. PFE's recent underperformance compared to the market, bearish technical indicators, and mixed analyst opinions suggest potential risks for investors.  Further research and careful consideration of the company's long-term growth strategy are essential before making any investment decisions.
